OurCrowd Portfolio Company SaNOtize Moves Forward with Anti-COVID Nitric Oxide Nasal Spray, Approved for Sale

OurCrowd portfolio company SaNOtize Research & Development Corp. has received interim approval to sell its COVID-19 treatment Nitric Oxide Nasal Spray (NONS). The spray is said to protect users from viruses that enter the body through the upper nasal pathways. The spray will be sold to the public in pharmacies in Israel, and has been registered to begin sales in New Zealand.

NONS will be distributed under the brand name EnovidTM and is expected to appear on pharmacy shelves in Israel by the summer. In New Zealand, SaNOtize has registered its nasal spray with the New Zealand Medicines and Medical Devices Safety Authority, which permits the company to distribute and sell NONS over the counter immediately.

Dr. Gilly Regev, the Israeli CEO and co-founder of SaNOtize, commented:

“The product we have developed, which kills viruses in the upper nasal pathways, will be delivered via a nasal spray bottle that contains a month’s supply for an individual. We look forward to updating the public in Israel and New Zealand with details on when Enovid will hit store shelves.”

Last week it was reported that SaNOtize and Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK announced results of clinical trials indicating that NONS represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. The study has been submitted to a leading medical journal for review and publication.

“Our novel formulation of Nitric Oxide for use in humans is designed to kill viruses in the upper airways, preventing them from incubating and spreading to the lungs. The pharmacology, toxicity, and safety data for use in humans has been well-established for decades,” said Dr. Chris Miller, Chief Science Officer and co-founder of SaNOtize. “Our innovative product design also allows the treatment to be self-administered effectively and affordably.”

OurCrowd is the most active venture firm in Israel but invests in companies globally. OurCrowd has targeted the Medtech/Biotech sector has an investment area of interest.


Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!

Sponsored Links by DQ Promote


 

Send this to a friend